Akeso Licenses Yixining to Jumpcan for PCSK9 Promotion in China
Akeso Biopharma (HKG: 9926) announced a partnership with Jumpcan Pharmaceutical (SHA: 600566) granting Jumpcan exclusive...
United Laboratories UBT251 Gets NMPA Nod for Sleep Apnea Trial
United Laboratories International Holdings Ltd (HKG: 3933) announced that the National Medical Products Administration (NMPA) has...
Wuhan YZY Biopharma Gets FDA Nod for M701 Phase Ib/II MPE Study
Wuhan YZY Biopharma Co., Ltd (HKG: 2496) announced that the U.S. Food and Drug Administration...
Amgen Q4 Revenue Grows 9% to $9.9B on Strong Product Sales
Amgen (NASDAQ: AMGN) reported fourth‑quarter 2025 revenue of USD 9.9 billion, up 9% year‑over‑year (YOY), bringing full‑year revenue...
Grand Pharmaceutical to Acquire API Firms for RMB 316 Million
Grand Pharmaceutical Group Limited (HKG: 0512) announced plans to acquire 100% equity in Hebei Grand...
Novo Nordisk Sales Reach DKK 309 Billion on GLP‑1 and Obesity Surge
Novo Nordisk (NYSE: NVO) reported 2025 global sales of DKK 309 billion (USD 48.9 billion), representing 10% year‑on‑year (YOY) growth...
Simcere Receives $40M Milestone from AbbVie for Trispecific Myeloma Drug
Simcere Pharmaceutical Group Ltd (HKG: 2096) announced it has received a USD 40 million near‑term milestone payment from...
Medtronic to Acquire CathWorks for $585M, Expand AI-Based FFRangio System
Medtronic Inc. (NYSE: MDT) announced it will exercise its option to acquire Israel-based medical device company...
TenNor Therapeutics Files Hong Kong IPO for Anti-Infective Pipeline
TenNor Therapeutics (Suzhou) Limited submitted its initial public offering (IPO) application to the Main Board...
BeBetter Med BEBT-701 Approved for Hypertension siRNA Trial
Guangzhou BeBetter Medicine Technology Co., Ltd. (SHA: 688759) announced that the National Medical Products Administration...
AbbVie Files Rinvoq for Vitiligo Approval in US and EU
AbbVie (NYSE: ABBV) announced it has submitted new indication applications to the U.S. Food and Drug...
Datroway TNBC sBLA Gets FDA Priority Review for Triple-Negative Breast Cancer
AstraZeneca (AZ, NASDAQ: AZN) and Daiichi Sankyo (TYO: 4568) announced that the U.S. Food and Drug Administration...
Bayer Nubeqa Gets NMPA Approval for Metastatic Prostate Cancer
Bayer AG (ETR: BAYN) announced that the National Medical Products Administration (NMPA) has approved Nubeqa (darolutamide)...
Daiichi Sankyo Discontinues DS-9606 ADC, Delays Dato-DXd Data
Daiichi Sankyo (TYO: 4568) announced it has discontinued internal development of DS-9606, a Claudin 6 (CLDN6)-targeting...
Insilico Medicine Doses First Patient in MEN2501 Phase I, Triggers $5M Menarini Milestone
Insilico Medicine (HKG: 3696) announced the first patient dosing in a Phase I clinical study...
PrimeGenX Therapeutics Files Hong Kong IPO for Pumecitinib Platform
PrimeGenX Therapeutics Co., Ltd., a Beijing‑based immuno‑inflammation biotech founded in 2016, made an initial public...
Hengrui Resubmits Camrelizumab-Apatinib BLA for HCC to FDA
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that the U.S. Food and Drug Administration...
Jumpcan Licenses PrimeGenX Pumecitinib Nasal Spray for Allergic Rhinitis
Jumpcan Pharmaceutical (SHA: 600566) announced a partnership with PrimeGenX Therapeutics Co., Ltd. granting Jumpcan exclusive...
ZEISS ARTEVO Gets NMPA Approval for China Ophthalmology Market
ZEISS Medical Technology announced that the National Medical Products Administration (NMPA) has approved the ARTEVO...
Venglustat Gaucher: Sanofi Meets Primary Endpoint in Phase 3 LEAP2MONO Study
Sanofi (NASDAQ: SNY) announced positive results from the LEAP2MONO phase 3 study (NCT05222906), showing venglustat met the...